Abstract
HIV infection has been a major global health problem for almost three decades. With the introduction of highly active antiretroviral therapy in 1996, and the advent of effective prophylaxis and management of opportunistic infections, AIDS mortality has decreased markedly. In developed countries, this once fatal infection is now being treated as a chronic condition. As a result, rates of morbidity and mortality from other medical conditions leading to end-stage liver, kidney and heart disease are steadily increasing in individuals with HIV. Presence of HIV infection used to be viewed as a contraindication to transplantation for multiple reasons: concerns for exacerbation of an already immunocompromised state by administration of additional immunosuppressants; the use of a limited supply of donor organs with unknown long-term outcomes; and, the risk of viral transmission to the surgical and medical staff. This Review examines open questions on kidney transplantation in patients infected with HIV-1 and clinical strategies that have resulted in good outcomes. It also describes the clinical concerns associated with the treatment of renal transplant recipients with HIV.
Key Points
-
Renal transplantation is both safe and effective in patients with HIV
-
Rejection rates in patients with HIV are increased, although these rejections respond to therapy
-
Several interactions between highly active antiretroviral therapy drugs and immunosuppressants exist, and they should be taken into careful consideration when devising immunosuppression regimens
-
Management of co-infection with hepatitis C virus and HIV is challenging, as progression rate of liver disease is increased in affected patients
-
Treatment and patient oversight by a team of specialists is critically important to the management of renal transplant recipients with HIV
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pardo, V. et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann. Intern. Med. 101, 429–434 (1984).
Rao, T. K. et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 310, 669–673 (1984).
Ross, M. J. & Klotman, P. E. Recent progress in HIV-associated nephropathy. J. Am. Soc. Nephrol. 13, 2997–3004 (2002).
Selik, R. M., Byers, R. H. Jr, & Dworkin, M. S. Trends in diseases reported on U. S. death certificates that mentioned HIV infection 1987–1999. J. Acquir. Immune Defic. Syndr. 29, 378–387 (2002).
Trullàs, J. C. et al. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res. Hum. Retroviruses 24, 1229–1235 (2008).
Choi, A. I. et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin. Infect. Dis. 45, 1633–1639 (2007).
Fine, D. M., Perazella, M. A., Lucas, G. M. & Atta, M. G. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs 68, 963–980 (2008).
Shahinian, V. et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am. J. Kidney Dis. 35, 884–888 (2000).
Cohen, A. H., Sun, N. C., Shapshak, P. & Imagawa, D. T. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod. Pathol. 2, 125–128 (1989).
Nochy, D. et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol. Dial. Transplant. 8, 11–19 (1993).
Monahan, M., Tanji, N. & Klotman, P. E. HIV-associated nephropathy: an urban epidemic. Semin. Nephrol. 21, 394–402 (2001).
Ahuja, T. S. et al. Is the prevalence of HIV-associated nephropathy decreasing? Am. J. Nephrol. 19, 655–659 (1999).
Winston, J. A. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med. 344, 1979–1984 (2001).
Abbott, K. C., Trespalacios, F. C., Agodoa, L. Y. & Ahuja, T. S. HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study. BMC Nephrol. 4, 5 (2003).
Rho, M. & Perazella, M. A. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr. Drug Saf. 2, 147–154 (2007).
Fichtenbaum, C. J. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr. Infect. Dis. Rep. 11, 84–92 (2009).
Tourret, J. et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin. J. Am. Soc. Nephrol. 6, 1241–1247 (2006).
Atta, M. G. et al. Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin. Infect. Dis. 45, 1625–1632 (2007).
Nolan, C. R. Strategies for improving long-term survival in patients with ESRD. J. Am. Soc. Nephrol. 16 (Suppl. 2), S120–S127 (2005).
Stock, P. G. et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76, 370–375 (2003).
Carter, J. T., Melcher, M. L., Carlson, L. L., Roland, M. E. & Stock, P. G. Thymoglobulin-associated CD4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am. J. Transplant. 6, 753–760 (2006).
Pelletier, S. J. et al. Review of transplantation in HIV patients during the HAART era. Clin. Transpl. 63–82 (2004).
Abbott, K. C., Swanson, S. J., Agodoa, L. Y. & Kimmel, P. L. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J. Am. Soc. Nephrol. 15, 1633–1639 (2004).
Roland, M. E. & Stock, P. G. Review of solid-organ transplantation in HIV-infected patients. Transplantation 75, 425–429 (2003).
Roland, M. E. et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am. J. Transplant. 8, 355–365 (2008).
Tan, H. P. et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation 78, 1683–1688 (2004).
Kumar, M. S. et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 67, 1622–1629 (2005).
Trullas, J. C. et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: differences between HIV-positive and HIV-negative patients. AIDS Res. Hum. Retroviruses 23, 1161–1165 (2007).
Gruber, S. A. et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation 86, 269–274 (2008).
Samuel, D., Weber, R., Stock, P., Duclos-Vallee, J. C. & Terrault, N. Are HIV-infected patients candidates for liver transplantation? J. Hepatol. 48, 697–707 (2008).
Carlson, L. Clinical management of the HIV-positive kidney transplant recipient. Nephrol. Nurs. J. 35, 559–567 (2008).
Bhagani, S., Sweny, P., Brook, G. & British HIV Association. Guidelines for kidney transplantation in patients with HIV disease. HIV Med. 7, 133–139 (2006).
Rouet, F. et al. CD4 percentages and total lymphocyte counts as early surrogate markers for pediatric HIV-1 infection in resource-limited settings. J. Trop. Pediatr. 52, 346–354 (2006).
Transplant Study For People with HIV [online], (2009).
O'Gorman, M. R. & Zijenah, L. S. CD4 T cell measurements in the management of antiretroviral therapy--A review with an emphasis on pediatric HIV-infected patients. Cytometry B. Clin. Cytom. 74 (Suppl. 1), S19–S26 (2008).
Sehgal, S. N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35 (Suppl. 3), S7–S14 (2003).
Roy, J., Paquette, J. S., Fortin, J. F. & Tremblay, M. J. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 46, 3447–3455 (2002).
Heredia, A. et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines: an approach to suppress R5 strains of HIV-1. Proc. Natl Acad. Sci. USA 100, 10411–10416 (2003).
Lesens, O., Deschênes, M., Steben, M., Bélanger, G. & Tsoukas, C. M. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J. Infect. Dis. 179, 1254–1258 (1999).
Jain, M., Chakravarti, A., Verma, V. & Bhalla, P. Seroprevalence of hepatitis viruses in patients infected with the human immunodeficiency virus. Indian J. Pathol. Microbiol. 52, 17–19 (2009).
Ragni, M. V., Nalesnik, M. A., Schillo, R. & Dang, Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 15, 552–528 (2009).
Luan, F. L. et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 85, 1601–1606 (2008).
Locke, J. E., Montgomery, R. A., Warren, D. S., Subramanian, A. & Segev, D. L. Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss. Arch. Surg. 144, 83–86 (2009).
Margolis, D. et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J. Acquir. Immune Defic. Syndr. 21, 362–370 (1999).
Kaur, R. et al. A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. AIDS Res. Ther. 3, 16–21 (2006).
Oestreich, K. J., Yoon, H., Ahmed, R. & Boss, J. M. NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181, 4832–4839 (2008).
Fruman, D. A., Klee, C. B., Bierer, B. E. & Burakoff, S. J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc. Natl Acad. Sci. USA 89, 3686–3690 (1992).
Argyropoulos, C. & Mouzaki, A. Immunosuppressive drugs in HIV disease. Curr. Top. Med. Chem. 6, 1769–1789 (2006).
Stock, P. G. & Roland, M. E. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 84, 563–571 (2007).
Wacher, V. J., Wu, C. Y. & Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13, 129–134 (1995).
Benet, L. Z., Cummins, C. L. & Wu, C. Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277, 3–9 (2004).
Frassetto, L. A. et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am. J. Transplant. 7, 2816–2820 (2007).
Jain, A. B. et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 9, 954–960 (2003).
Jain, A. K. et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl. 8, 841–845 (2002).
Vogel, M. et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl. 10, 939–944 (2004).
Guaraldi, G. et al. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant. Proc. 38, 1138–1140 (2006).
Niwa, T., Murayama, N., Emoto, C. & Yamazaki, H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. Drug Metab. 9, 20–33 (2008).
Guiard-Schmid, J. B., Poirier, J. M., Bonnard, P. & Meynard, J. L. Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J. Acquir. Immune Defic. Syndr. 41, 393–394 (2006).
Kiser, J. J., Lichtenstein, K. A., Anderson, P. L. & Fletcher, C. V. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy 26, 511–514 (2006).
Fulco, P. P., Vora, U. B. & Bearman, G. M. Acid suppressive therapy and the effects on protease inhibitors. Ann. Pharmacother. 40, 1974–1983 (2006).
Rashid, A. et al. The impact of hepatitis C infection and antiviral therapy on clinical outcome in renal transplantation recipients. Saudi J. Kidney Dis. Transpl. 10, 31–35 (1999).
Miró, J. M. et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005) [Spanish]. Enferm. Infecc. Microbiol. Clin. 23, 353–362 (2005).
Kovesdy, C. P. & Kalantar-Zadeh, K. Bone and mineral disorders in pre-dialysis CKD. Int. Urol. Nephrol. 40, 427–440 (2008).
Mitterbauer, C. & Oberbauer, R. Bone disease after kidney transplantation. Transpl. Int. 21, 615–624 (2008).
Dolan, S. E., Carpenter, S. & Grinspoon, S. Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. J. Acquir. Immune. Defic. Syndr. 45, 161–167 (2007).
Kalyani, R. R., Gavini, S. & Dobs, A. S. Male hypogonadism in systemic disease. Endocrinol. Metab. Clin. North Am. 36, 333–348 (2007).
Jacobson, D. L., Spiegelman, D., Knox, T. K. & Wilson, I. B. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J. Acquir. Immune Defic. Syndr. 49, 298–308 (2008).
Pollet, C., Paul, S. M. & Morgan, R. Immunizations in the HIV-infected patient. N. J. Med. 99, 23–31 (2002).
Twardowski, Z. J. Sodium, hypertension, and an explanation of the “lag phenomenon” in hemodialysis patients. Hemodial. Int. 12, 412–425 (2008).
Flint, O. P. et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol. Pathol. 37, 65–77 (2009).
Bobadilla, N. A. & Gamba, G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am. J. Physiol. Renal. Physiol. 293, F2–F9 (2007).
Reynolds, L. R. & Tannock, L. R. Management of new-onset diabetes mellitus after transplantation. Postgrad. Med. 120, 60–66 (2008).
Corsini, A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc. Drugs Ther. 17, 265–285 (2003).
Goedert, J. J. et al. Spectrum of AIDS-associated malignant disorders. Lancet 351, 1833–1839 (1998).
Serraino, D., Piselli, P. & Immunosuppression and Cancer Study Group. Cancer cohort consortium approach: cancer epidemiology in immunosuppressed groups. Methods Mol. Biol. 471, 409–419 (2009).
Engels, E. A. et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer 123, 187–194 (2008).
MacDonald, D. C., Nelson, M., Bower, M. & Powles, T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J. Gastroenterol. 14, 1657–1663 (2008).
Chin-Hong, P. V. & Palefsky, J. M. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol. Ther. 18, 67–76 (2005).
Mazuecos, A. et al. Renal transplantation in HIV-infected patients in Spain [Spanish]. Nefrologia 26, 113–120 (2006).
Roland, M. E., Carlson, L. L., Frassetto, L. A. & Stock, P. G. Solid organ transplantation: referral, management, and outcomes in HIV-infected patients. AIDS Read. 16, 664–668, 675–678 (2006).
USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in person infected with Human Immunodeficiency Virus. MMWR 48, 10 (1999).
Acknowledgements
Drs. Frassetto and Stock receive support from NIH NIAID grant AI052748, “Solid Organ Transplantation in HIV”.
Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frassetto, L., Tan-Tam, C. & Stock, P. Renal transplantation in patients with HIV. Nat Rev Nephrol 5, 582–589 (2009). https://doi.org/10.1038/nrneph.2009.140
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.140
This article is cited by
-
Health-related quality of life and associated factors in HIV-positive transplant candidates and recipients from a HIV-positive donor
Quality of Life Research (2022)
-
Therapeutic management of HIV-infected patients with chronic kidney disease
Journal of Nephrology (2020)
-
Renal Transplantation in HIV-Positive Recipients
Current Infectious Disease Reports (2010)